Lessons From In Re Rigel Pharmaceuticals

more+
less-

Originally published in Law360, New York (September 19, 2012, 10:56 AM ET)

In In re Rigel Pharmaceuticals Inc. Securities Litigation (9th Cir. Sept. 6, 2012), the United States Court of Appeals for the Ninth Circuit affirmed the dismissal of a putative securities class action against Rigel Pharmaceuticals Inc., certain of Rigel’s directors and officers, and underwriters of Rigel’s February 2008 stock offering.

In a published opinion, the court held plaintiffs failed to sufficiently plead a false or misleading statement, and that the complaint’s allegations failed to meet the heightened requirements for pleading scienter under the Private Securities Litigation Reform Act of 1995. In so holding, the Ninth Circuit held that mere disagreement with statistical methodology employed in a clinical drug trial is not sufficient to state a securities fraud claim.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Business Organization Updates, Business Torts Updates, Civil Procedure Updates, Science, Computers & Technology Updates, Securities Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Lane Powell PC | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »